Educational Content

Clinical Practice

SNMMI 2020 Annual Meeting - TS Summer Program: Nuts and Bolts of New Targeted Radionuclide Therapies
SNMMI 2020 Annual Meeting - TS Educator's Forum: Therapy Panel Discussion

Dosimetry

CE46: Joint SNMMI-ASTRO Session: Individualized Dosimetry for Theranostics
CE72: Quantitative Imaging for Dosimetry in Radionuclide Imaging and Therapy
CE02: Imaging and Guided Therapy and Dosimetry

General

JNM CE/SAM (June 2018): Alpha-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 1
JNM CE/SAM (July 2018): Alpha-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 2
CE10: Community-Based Theranostics
CE69: Theranostics 101: Practical Clinical Aspects - Highlight Country Session
CE65: Radioisotope Production for Theranostics
CE39: Current State of Development of New Theranostic Agents
CE79: Joint AAPM/SNMMI Symposium - Bridging Nuclear Medicine and Radiation Therapy Towards Precision Oncology
CE43: Saul Hertz Award Symposium: Emerging Theranostic Targets

General

SS77: Image Guided Therapy
CE59: Receptor Targeted Radionuclide Therapy for Pediatric Cancers
TS07: Theranostics: Imaging and Therapy - I
CE73: Radiological Protection in Therapy with Radiopharmaceuticals; Prospects from ICRP TG101
JNMT (September 2019) An Introduction to Newer PET Diagnostic Agents and Related Therapeutic Radiopharmaceuticals
Clinical Trials Webinar Series - Review of Radiopharmaceuticals Used in Radionuclide Therapy
The Emerging Role of Theranostics in Nuclear Medicine
Clinical Trials Webinar Series - Preparing Sites for 177Lu-Radioligand Therapy Programs

Liver

CE50: Liver Directed Therapy
JNM CE/SAM (November 2018): Treatment of Primary Liver Tumors and Liver Metastases, Part 1: Nuclear Medicine Techniques

NETs

Clinical Trials Webinar Series - 177 – Lutetium DOTATATE – Incorporating it in Your Clinic
CE28: Present and Future of PRRT in the Treatment of Neuroendocrine Tumors
TS12: Lu-177 Dotatate Therapy: A Radiologist and Technologist Perspective
CE57: The Era of PRRT: Personalization, Integration and Future Perspectives
CE60: Neuroendocrine Tumor Diagnosis and Therapy
CE91: Sequencing Therapies for Metastatic Neuroendocrine Tumors - Joint SNMMI/NANETS Session
JNMT (September 2018) Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division
Quarterly SNMMI-TS Webinar Series: 177Lu-DOTATATE Administration in the Nuclear Medicine Department
CE57: Theranostics of Neuroendocrine Tumors: PRRT
CE04: Using Lutetium LU 177 Dotatate – Nuts and Bolts Experience
Joint SNMMI/NANETS Webinar: PRRT Procedure Guidelines: How to Treat - Procedure Standard for Somatostatin Receptor Based PRRT with Lu-DOTATATE
Joint SNMMI/NANETS Webinar: PRRT Indication Guidelines – Who to Treat
SNMMI 2020 Annual Meeting - TS Educator's Forum: Radionuclide Therapy

Prostate

CE08: Prostate Cancer Nuts and Bolts: Diagnosis and Therapy
PET Center of Excellence Newsletter Article: PSMA and Prostate Cancer, a New Beginning
CE08: Theranostics and Bone Targeting Radiopharmaceutical Therapy in Prostate Cancer
SNMMI 2020 Annual Meeting: PSMA Imaging and Therapy Agents
Changing the Standard of Care in Prostate Cancer with Advances in Nuclear Medicine, PET and Theranostics

Thyroid

CE06: General Clinical Nuclear Medicine Council Award Lectureship: The Evolving Paradigm of Radioiodine Therapeutics for Thyroid Cancer
CE15: Differentiated Thyroid Cancer Theranostics Practicum
CE83: Imaging and Therapy for Thyroid Cancer: The Theranostics Paradigm
TS17: Differentiated Thyroid Cancer Management and Therapy Update
JNM CE/SAM (August 2018): A Matter of Controversy: Is Radioiodine Therapy Favorable in Differentiated Thyroid Carcinoma?
JNM CE/SAM (August 2018): Controversial Issues in Thyroid Cancer Management
JNM CE/SAM (January 2019): Current Treatment Strategies in Metastasized Differentiated Thyroid Cancer
CE15: Differentiated Thyroid Cancer Theranostics Practicum